Myriad Genetics (MYGN) reported 213.3millioninrevenueforthequarterendedSeptember2024,representingayear−over−yearincreaseof11.20.06 for the same period compares to -0.03ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof209.82 million, representing a surprise of +1.66%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being $0.02.While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...